125 related articles for article (PubMed ID: 23298945)
21. Pharmacokinetic profile of the microtubule stabilizer patupilone in tumor-bearing rodents and comparison of anti-cancer activity with other MTS in vitro and in vivo.
O'Reilly T; Wartmann M; Brueggen J; Allegrini PR; Floersheimer A; Maira M; McSheehy PM
Cancer Chemother Pharmacol; 2008 Nov; 62(6):1045-54. PubMed ID: 18301895
[TBL] [Abstract][Full Text] [Related]
22. Estrogen-mediated post transcriptional down-regulation of P-glycoprotein in MDR1-transduced human breast cancer cells.
Mutoh K; Tsukahara S; Mitsuhashi J; Katayama K; Sugimoto Y
Cancer Sci; 2006 Nov; 97(11):1198-204. PubMed ID: 16925584
[TBL] [Abstract][Full Text] [Related]
23. A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents.
Colabufo NA; Contino M; Berardi F; Perrone R; Panaro MA; Cianciulli A; Mitolo V; Azzariti A; Quatrale A; Paradiso A
Toxicol In Vitro; 2011 Feb; 25(1):222-30. PubMed ID: 21078380
[TBL] [Abstract][Full Text] [Related]
24. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic.
Ma B; Chai S; Li N; To KK; Kan WL; Yang D; Lin G
Int J Pharm; 2012 Mar; 424(1-2):33-9. PubMed ID: 22226881
[TBL] [Abstract][Full Text] [Related]
25. Effect of Stemona curtisii root extract on P-glycoprotein and MRP-1 function in multidrug-resistant cancer cells.
Limtrakul P; Siwanon S; Yodkeeree S; Duangrat C
Phytomedicine; 2007 Jun; 14(6):381-9. PubMed ID: 17467965
[TBL] [Abstract][Full Text] [Related]
26. Induction of multidrug resistance in MOLT-4 cells by anticancer agents is closely related to increased expression of functional P-glycoprotein and MDR1 mRNA.
Liu ZL; Onda K; Tanaka S; Toma T; Hirano T; Oka K
Cancer Chemother Pharmacol; 2002 May; 49(5):391-7. PubMed ID: 11976833
[TBL] [Abstract][Full Text] [Related]
27. Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate.
Wang C; Zhang JX; Shen XL; Wan CK; Tse AK; Fong WF
Biochem Pharmacol; 2004 Sep; 68(5):843-55. PubMed ID: 15294447
[TBL] [Abstract][Full Text] [Related]
28. Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance.
Newman MJ; Rodarte JC; Benbatoul KD; Romano SJ; Zhang C; Krane S; Moran EJ; Uyeda RT; Dixon R; Guns ES; Mayer LD
Cancer Res; 2000 Jun; 60(11):2964-72. PubMed ID: 10850444
[TBL] [Abstract][Full Text] [Related]
29. Thyroid hormone export from cells: contribution of P-glycoprotein.
Mitchell AM; Tom M; Mortimer RH
J Endocrinol; 2005 Apr; 185(1):93-8. PubMed ID: 15817830
[TBL] [Abstract][Full Text] [Related]
30. Interaction of tomato lectin with ABC transporter in cancer cells: glycosylation confers functional conformation of P-gp.
Molnár J; Kars MD; Gündüz U; Engi H; Schumacher U; Van Damme EJ; Peumans WJ; Makovitzky J; Gyémánt N; Molnár P
Acta Histochem; 2009; 111(4):329-33. PubMed ID: 19124148
[TBL] [Abstract][Full Text] [Related]
31. Can flavonoids from honey alter multidrug resistance?
Jaganathan SK
Med Hypotheses; 2011 Apr; 76(4):535-7. PubMed ID: 21247706
[TBL] [Abstract][Full Text] [Related]
32. Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells.
Zhao YX; Liang WQ; Wang Y; Liu DX
Pharmazie; 2011 Feb; 66(2):130-5. PubMed ID: 21434576
[TBL] [Abstract][Full Text] [Related]
33. Intracellular P-glycoprotein in multidrug resistant tumor cells.
Arancia G; Molinari A; Calcabrini A; Meschini S; Cianfriglia M
Ital J Anat Embryol; 2001; 106(2 Suppl 1):59-68. PubMed ID: 11729998
[TBL] [Abstract][Full Text] [Related]
34. Novel approaches to reversing anti-cancer drug resistance using gene-specific therapeutics.
Kobayashi H; Takemura Y; Miyachi H
Hum Cell; 2001 Sep; 14(3):172-84. PubMed ID: 11774737
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of protein glycosylation reverses the MDR phenotype of cancer cell lines.
Wojtowicz K; Januchowski R; Nowicki M; Zabel M
Biomed Pharmacother; 2015 Aug; 74():49-56. PubMed ID: 26349962
[TBL] [Abstract][Full Text] [Related]
36. Bisbibenzyl derivatives sensitize vincristine-resistant KB/VCR cells to chemotherapeutic agents by retarding P-gp activity.
Xi GM; Sun B; Jiang HH; Kong F; Yuan HQ; Lou HX
Bioorg Med Chem; 2010 Sep; 18(18):6725-33. PubMed ID: 20724170
[TBL] [Abstract][Full Text] [Related]
37. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression.
Chen J; Lu L; Feng Y; Wang H; Dai L; Li Y; Zhang P
Cancer Lett; 2011 Jan; 300(1):48-56. PubMed ID: 20934246
[TBL] [Abstract][Full Text] [Related]
38. Euphorbiasteroid reverses P-glycoprotein-mediated multi-drug resistance in human sarcoma cell line MES-SA/Dx5.
Choi JS; Kang NS; Min YK; Kim SH
Phytother Res; 2010 Jul; 24(7):1042-6. PubMed ID: 19960428
[TBL] [Abstract][Full Text] [Related]
39. Persistent reversal of P-glycoprotein-mediated daunorubicin resistance by tetrandrine in multidrug-resistant human T lymphoblastoid leukemia MOLT-4 cells.
Liu ZL; Hirano T; Tanaka S; Onda K; Oka K
J Pharm Pharmacol; 2003 Nov; 55(11):1531-7. PubMed ID: 14713364
[TBL] [Abstract][Full Text] [Related]
40. COX-2 contributes to P-glycoprotein-mediated multidrug resistance via phosphorylation of c-Jun at Ser63/73 in colorectal cancer.
Sui H; Zhou S; Wang Y; Liu X; Zhou L; Yin P; Fan Z; Li Q
Carcinogenesis; 2011 May; 32(5):667-75. PubMed ID: 21296766
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
